for the Period Ended 31 March 2024
Directors report | |
Profit and loss | |
Balance sheet | |
Additional notes | |
Community Interest Report |
Directors' report period ended
The directors present their report with the financial statements of the company for the period ended 31 March 2024
Principal activities of the company
Directors
The director shown below has held office during the whole of the period from
1 April 2023
to
31 March 2024
The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006
This report was approved by the board of directors on
And signed on behalf of the board by:
Name:
Status: Director
for the Period Ended
2024 | 2023 | |
---|---|---|
|
£ |
£ |
Turnover: |
|
|
Cost of sales: |
(
|
(
|
Gross profit(or loss): |
( |
|
Distribution costs: |
|
|
Administrative expenses: |
(
|
(
|
Other operating income: |
|
|
Operating profit(or loss): |
( |
( |
Interest receivable and similar income: |
|
|
Interest payable and similar charges: |
|
|
Profit(or loss) before tax: |
( |
( |
Tax: |
|
|
Profit(or loss) for the financial year: |
( |
( |
As at
Notes | 2024 | 2023 | |
---|---|---|---|
|
£ |
£ |
|
Fixed assets | |||
Intangible assets: |
|
|
|
Tangible assets: |
|
|
|
Investments: |
|
|
|
Total fixed assets: |
|
|
|
Current assets | |||
Stocks: |
|
|
|
Debtors: |
|
|
|
Cash at bank and in hand: |
|
|
|
Investments: |
|
|
|
Total current assets: |
|
|
|
Prepayments and accrued income: |
|
|
|
Creditors: amounts falling due within one year: |
|
|
|
Net current assets (liabilities): |
|
|
|
Total assets less current liabilities: |
|
|
|
Creditors: amounts falling due after more than one year: |
|
|
|
Provision for liabilities: |
|
|
|
Accruals and deferred income: |
|
|
|
Total net assets (liabilities): |
|
|
|
Members' funds | |||
Profit and loss account: |
|
|
|
Total members' funds: |
|
|
The notes form part of these financial statements
This report was approved by the board of directors on
and signed on behalf of the board by:
Name:
Status: Director
The notes form part of these financial statements
for the Period Ended 31 March 2024
Basis of measurement and preparation
for the Period Ended 31 March 2024
2024 | 2023 | |
---|---|---|
Average number of employees during the period |
|
|
The company was established via a grant from the University of Oxford and was incorporated as a Community Interest Company on 25 March 2021. The company was founded to provide benefit to health care innovators, regulators, researchers, commissioners and those involved with health technology assessment, via research, education, training and consultancy. Company activity has been less frequent this year owing to the Director’s other professional commitments but continues to collaborate with a range of individuals and organisations in the UK and beyond to further the work surrounding the IDEAL methodology.
The company’s stakeholders consist of, but are not limited to health care innovators, regulators, researchers, commissioners and those involved with health technology assessment as well as patients. By focusing its efforts on improving the safety and effectiveness of evaluating surgical innovation within these key groups, it is hoped that patients internationally will benefit. As such, consultation with stakeholders is at the very core of the company’s mission and this process has continued throughout the 23/24 financial year.
No remuneration was received
No transfer of assets other than for full consideration
This report was approved by the board of directors on
22 November 2024
And signed on behalf of the board by:
Name: Prof. Peter McCulloch
Status: Director